Mathias Uhlen research is focused on protein science, antibody engineering and precision medicine and ranges from basic research in human and microbial biology to more applied research, including clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. His research has resulted in more than 600 publications and he is co-founder of 12 biotech companies. Since 2003, he has led an international effort to systematically map the human proteome and transcriptome to create a Human Protein Atlas using antibodies and various omics technologies. This effort has so far resulted the Tissue Atlas (2015) showing the distribution of proteins across human tissues and organs, the Cell Atlas (2016) showing the subcellular location of human proteins in single cells and the Pathology Atlas (2017) showing how cancer patient survival is tied to RNA and protein levels. He is member of the National Academy of Engineering (NAE) in USA, the Royal Swedish Academy of Science (KVA), the Swedish Academy of Engineering Science (IVA) and the European Molecular Biology Organization (EMBO). He is the President of the European Federation of Biotechnology and is chairing the International Working Group for Antibody Validation (IWGAV). From 2010-2015, he was the founding Director of the Science for Life Laboratory (SciLifeLab) which is a Swedish national center for molecular bioscience.
Abstracts this author is presenting: